Adverum Biotechnologies Announces 3-Year Efficacy and Safety

- Patients in OPTIC continue to experience long-term benefit from Ixo-vec through 3 years of follow-up, including maintenance of vision, durability of anatomical improvements and sustained reduction in anti-VEGF

Related Keywords

United Kingdom , United States , San Francisco , California , American , Laurent Fischer , Carld Regillo , Carl Regillo , Adverum Biotechnologies Inc , European Medicines Agency , Clinical Program Milestones , Retina Service At Wills Eye Hospital , Exchange Commission , American Academy Of Ophthalmology , Healthcare Products Regulatory Agency , Drug Administration , Retina Subspecialty Day , American Academy , Extension Data , Gene Therapy , Preliminary Data , Year Results From , Protein Data Highlights , Baseline Characteristics , Clinical Program , Program Milestones , Retina Service , Wills Eye Hospital , Fast Track , Innovation Passport , Private Securities Litigation Reform Act , Quarterly Report ,